Marketdash
Back to News

Two Healthcare Stocks Flashing Overbought Warning Signs

MarketDash Editorial Team
6 days ago
Exact Sciences and Haemonetics are showing extreme RSI readings above 89, suggesting these momentum darlings might be due for a breather after massive recent runs.

If you're the type of investor who pays attention to momentum indicators, two healthcare stocks might deserve a closer look right now—and not necessarily in a good way.

As of December 2, 2025, both companies are flashing RSI readings that would make even optimistic traders pause. The Relative Strength Index, for those unfamiliar, measures a stock's strength on up days versus down days. It's basically a momentum thermometer that helps traders gauge whether a stock might be running too hot. When the RSI climbs above 70, conventional wisdom says the asset is overbought. These two? They're way past that threshold.

Exact Sciences Corp

Exact Sciences Corp. (EXAS) is sitting on an RSI of 89.8, which is about as overbought as it gets. The cancer screening company has had quite the month, with shares climbing roughly 51% after Abbott Laboratories (ABT) announced on November 20 that it would acquire Exact Sciences for $105 per common share. The deal values the company at approximately $21 billion in total equity, with an estimated enterprise value around $23 billion—making it the largest transaction of the year in the global healthcare sector.

The stock has been on a tear, reaching a 52-week high of $101.87. Shares closed at $101.20 on Monday, down just 0.1%. The company also sports a momentum score of 91.33, according to stock ratings data.

Haemonetics Corp

Not far behind is Haemonetics Corp (HAE), with an RSI reading of 89.4. The blood management solutions company posted strong second-quarter results on November 6 that sent investors rushing in. Haemonetics reported earnings of $1.27 per share, handily beating the analyst consensus of $1.11. Revenue came in at $327.316 million, also topping estimates of $311.399 million. The company sweetened the pot by raising its fiscal 2026 EPS guidance.

The market responded enthusiastically—perhaps too enthusiastically. Shares have jumped around 61% over the past month, hitting a 52-week high of $88.31. On Monday, the stock closed at $80.96, down 0.5%.

For both companies, the fundamentals driving the rallies are real. Exact Sciences has a definitive acquisition agreement from a major player, and Haemonetics delivered legitimately impressive earnings. But momentum indicators exist for a reason. When stocks run this hard this fast, they often need time to digest those gains. Whether that means a pullback, consolidation, or just a breather depends on broader market conditions and company-specific news flow. But with RSI readings pushing 90, these stocks are certainly worth watching closely if you're thinking about initiating or adding to positions.

Back to News

Two Healthcare Stocks Flashing Overbought Warning Signs

MarketDash Editorial Team
6 days ago
Exact Sciences and Haemonetics are showing extreme RSI readings above 89, suggesting these momentum darlings might be due for a breather after massive recent runs.

If you're the type of investor who pays attention to momentum indicators, two healthcare stocks might deserve a closer look right now—and not necessarily in a good way.

As of December 2, 2025, both companies are flashing RSI readings that would make even optimistic traders pause. The Relative Strength Index, for those unfamiliar, measures a stock's strength on up days versus down days. It's basically a momentum thermometer that helps traders gauge whether a stock might be running too hot. When the RSI climbs above 70, conventional wisdom says the asset is overbought. These two? They're way past that threshold.

Exact Sciences Corp

Exact Sciences Corp. (EXAS) is sitting on an RSI of 89.8, which is about as overbought as it gets. The cancer screening company has had quite the month, with shares climbing roughly 51% after Abbott Laboratories (ABT) announced on November 20 that it would acquire Exact Sciences for $105 per common share. The deal values the company at approximately $21 billion in total equity, with an estimated enterprise value around $23 billion—making it the largest transaction of the year in the global healthcare sector.

The stock has been on a tear, reaching a 52-week high of $101.87. Shares closed at $101.20 on Monday, down just 0.1%. The company also sports a momentum score of 91.33, according to stock ratings data.

Haemonetics Corp

Not far behind is Haemonetics Corp (HAE), with an RSI reading of 89.4. The blood management solutions company posted strong second-quarter results on November 6 that sent investors rushing in. Haemonetics reported earnings of $1.27 per share, handily beating the analyst consensus of $1.11. Revenue came in at $327.316 million, also topping estimates of $311.399 million. The company sweetened the pot by raising its fiscal 2026 EPS guidance.

The market responded enthusiastically—perhaps too enthusiastically. Shares have jumped around 61% over the past month, hitting a 52-week high of $88.31. On Monday, the stock closed at $80.96, down 0.5%.

For both companies, the fundamentals driving the rallies are real. Exact Sciences has a definitive acquisition agreement from a major player, and Haemonetics delivered legitimately impressive earnings. But momentum indicators exist for a reason. When stocks run this hard this fast, they often need time to digest those gains. Whether that means a pullback, consolidation, or just a breather depends on broader market conditions and company-specific news flow. But with RSI readings pushing 90, these stocks are certainly worth watching closely if you're thinking about initiating or adding to positions.